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Background: The US Food and Drug Administration approved in 2015 the use of deep brain stimulation for
Parkinson disease after “four years duration and with recent onset of motor complications”. The aim of this study
was to identify neurosurgeons’ attitudes and perspectives around the use of deep brain stimulation for Parkinson
disease earlier in the disease course.
Methods: An anonymous survey examining attitudes and perceptions towards deep brain stimulation practice and
timing in Parkinson disease was developed by the study team and distributed by the American Society for
Stereotactic and Functional Neurosurgeons to its members. Results from 32 subjects with answers to at least 50%
of the survey were included. Data were analyzed with descriptive statistics and chi-square test.
Results: Motor fluctuations, dyskinesia, quality of life impairment, and medically refractory tremor were the most
important reasons to proceed with deep brain stimulation, which was overall considered more useful after the
onset of motor symptoms. Unresponsiveness to levodopa, cognitive impairment, and unclear diagnosis were
important reasons not to consider deep brain stimulation. Earlier surgery was considered to be less risky
compared to later in the disease progression. Ten out of 25 neurosurgeons reported considering deep brain
stimulation as a therapeutic option after a minimum disease duration of three to four years.
Conclusions: We conclude that neurosurgeons support the use of earlier deep brain stimulation, but not preceding
motor complications. Further research surrounding the benefits and adverse effects of earlier deep brain stim
ulation is needed to guide practice and better inform potential candidates.

1. Introduction
Subthalamic nucleus (STN) and Globus Pallidus pars interna (GPi)
deep brain stimulation (DBS) for Parkinson disease (PD) are effective in
decreasing dyskinesia, motor fluctuations, and tremor, as well as
improving quality of life [1–3]. With disease progression, axial and gait
problems arise, which are challenging to treat with DBS [4,5]. To
maximize the benefits of DBS before gait and non-motor symptoms
predominate, an interest towards earlier use of DBS has been observed in
the past decade [2]. Among the benefits cited supporting the earlier use
of DBS are the potential to reduce loss of social function and rates of
early retirement [6–8]; and reduction in health care costs [8–10].
In addition, early results suggested that quality of life may be

considerably improved by STN DBS in patients younger than 60 [11], as
there is a potential correlation between age at disease onset and time to
development of dyskinesia and motor fluctuations [12]. Considering
that patients who develop PD before the age of 40 are at high risk of
levodopa-induced complications, there may be an increased role for DBS
in younger patients [13].
Earlier use of DBS was first shown to be beneficial in an open label
study published in 2007 [14], and further investigated in the EAR
LYSTIM trial [4,15]. This large study (n = 251) included patients
younger than 61 years (mean age at inclusion was 52.6 years) with PD
symptoms for at least four years (mean disease duration was 7.5 years),
motor complications for up to three years (mean duration of complica
tions was 1.7 years), and no impaired psychosocial functioning [15]. In
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2015, following the publication of the EARLYSTIM trial results, the
FDA’s approval of Medtronic devices for DBS was extended to patients
with at least four years of PD and recent onset of motor complications
[16]. The possibility of expanding DBS use to before the onset of motor
complications (“early DBS”) was investigated in a pilot study including
30 subjects; it demonstrated a reduction in medications [17] and slower
progression of rest tremor in patients undergoing DBS [18]. However,
larger clinical studies remain needed around early DBS use in PD.
Despite the positive results of EARLYSTIM and the most recent FDA
approval for STN DBS, physician surveys and interview studies have
found a wide range of disease duration requirements prior to DBS
referral, with an average of less than four and up to six years depending
on the survey, and some physicians reporting no minimum duration
[19]. In light of the lack of guidance regarding when to consider DBS,
the shifting to earlier and earlier uses of DBS, and the lack of consensus
among experts on the merits of earlier DBS, we sought to investigate
functional neurosurgeons’ perspectives, as they play an important role
in determining patient candidacy.

variables had answers by more than five subjects. Data were analyzed
using IBM SPSS Statistics for Windows.
3. Results
About a third of physicians had completed fellowship (11/32,
34.38%) or residency (9/31, 29%) >20 years prior to completing the
survey. Recent fellowship graduates (10/32, 31.25%) and residency
graduates (9/31, 29%) within the past five years were similarly repre
sented. More than a third of participants (12/32, 37.5%) reported per
forming 11 to 20 DBS surgeries for PD per year, while only 25% (8/32)
perform over 50 per year. The STN was the most frequently preferred
target for DBS (20/28, 71.43%), while 17.86% (5/28) of the surgeons
used STN and GPi equally (Table 1).
Neurosurgeons were fairly equally distributed among those who
required a strict cut-off of improvement in total Unified Parkinson Dis
ease Rating Scale (UPDRS) Part III motor scores after levodopa challenge
prior to DBS (13/27, 48.15%) and those (14/27, 51.85%) who did not.
Those who answered that they did, were given options regarding the
improvement they required prior to DBS and could select multiple
choices. Among the main standard cut-offs for surgical candidacy were
medically-refractory tremor (listed by 8/13, 61.54%), a 30-point
improvement in UPDRS or Movement Disorder Society-sponsored
UPDRS revision (MDS-UPDRS) off to on scores (6/13, 46.15%), and a
33% improvement in UPDRS or MDS-UPDRS off to on scores (6/13,
46.15%). There was a free-text answer citing 30% improvement albeit in
an unspecified scoring system.
When asked about the three most important medications that must
be tried prior to considering a patient for DBS, carbidopa/levodopa
immediate release (listed by 23/28, 82.14%), controlled released car
bidopa/levodopa (17/28, 60.71%), and dopamine agonists (15/28,

2. Methods
A 19-question online survey comprising of Likert-type, multiple
choice, and rank-order questions examining attitudes and perceptions
towards use and timing of DBS in PD was developed drawing upon re
sults from a pilot interview survey [20] and expert opinion (movement
disorder neurologists) to evaluate attitudes around DBS and its timing in
PD. The developing survey drafts were also reviewed by patient advo
cates and clinical experts from the Parkinson’s Foundation, Parkinson’s
Alliance, and Michael J. Fox Foundation, to ensure quality control for
content, readability, survey navigation and item clarity. The first part of
the survey asked questions about clinical experience and practice,
including years of practice and number of DBS cases per year. Remaining
questions focused on patient selection, target choice, and thoughts on
earlier DBS. The survey was piloted among members of the study team.
Institutional Review Board approval was obtained from the institutions
of the two co-PI’s (Michigan State University, STUDY00002041, and
Weill Cornell Medicine, # 1901019902).

Table 1
Survey responders’ experience and DBS practice data.
Surgeon
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

2.1. Survey distribution
We received approval from the American Society for Stereotactic and
Functional Neurosurgeons (ASSFN) to distribute the survey among its
members (see Survey Instrument, Supplemental Digital Content 1). The
ASSFN Administrator sent the initial invitation with the link to the
survey to the members via email on September 17, 2019, and a reminder
was sent on October 7. Data collection was completed on October 22,
2019. All responses were anonymous.
2.2. Data preparation
Forty-three survey responses were obtained. We excluded from
analysis six responses as >50% of their survey was incomplete. Another
five responses were removed due to duplication of IP addresses. The
final dataset for analysis consisted of 32 unique participants.
2.3. Data analysis
All variables were nominal or ordinal. Descriptive statistics are re
ported as frequencies and round percentages. We used chi-square test to
compare responses to the following questions based on years of clinical
experience (defined as number of years since fellowship) and numbers of
surgeries: (1) presence or absence of a cut off prior to proceeding with
surgery; (2) minimum duration of disease required prior to proceeding
with DBS; (3) whether the current FDA approval for DBS in PD is
considered earlier use or not; and (4) how many years after diagnosis for
implantation would the use of DBS be considered earlier use. All selected

Years since
end of
fellowship
>20
0–5
>20
0–5
0–5
11–15
6–10
16–20
6–10
>20
6–10
11–15
0–5
0–5
>20
>20
>20
>20
6–10
6–10
0–5
>20
>20
>20
16–20
11–15
6–10
0–5
0–5
>20
0–5
0–5

Years since
end of
residency
>20
0–5
>20
0–5
0–5
11–15
11–15
16–20
6–10
>20
6–10
11–15
0–5
n/a
>20
>20
>20
>20
0–5
6–10
0–5
>20
>20
>20
16–20
11–15
>20
0–5
0–5
>20
6–10
0–5

Average number
of DBS surgeries
for PD per year
>50
21–30
>50
11–20
11–20
0–10
11–20
>50
>50
11–20
31–40
11–20
11–20
31–40
31–40
>50
21–30
0–10
>50
11–20
0–10
31–40
11–20
>50
21–30
>50
11–20
21–30
11–20
31–40
11–20
11–20

Most common
DBS target (STN
versus GPi)
STN
STN
GPi
both
STN
n/a
STN
STN
STN
STN
STN
both
GPi
STN
STN
GPi
STN
n/a
n/a
STN
n/a
STN
STN
STN
STN
STN
STN
both
both
STN
STN
Both

Abbreviations: DBS, deep brain stimulation; PD, Parkinson disease; STN, sub
thalamic nucleus; GPi, globus pallidus pars interna; n/a, not available.
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hemorrhage and cognitive decline with increasing age (13/23, 56.5%).
In terms of hardware, most neurosurgeons counsel regarding the risks of
hardware complications (23/25, 92%) and the type and location of the
implant (21/25, 84%). Twenty-four out of 25 neurosurgeons also discuss
one or more technical features of available devices and stimulation pa
rameters, including the option of rechargeable batteries (21/24 87.5%),
MRI compatibility (20/24, 83.3%), and the differences between
segmented and non-segmented leads (18/24, 75%).
Most surgeons (22/25, 88%) answered that they have DBS confer
ences. All the respondents noted the presence of the treating neurologist
and neurosurgeon in the conferences, with 90% (20/22) noting the
participation of a neuropsychologist. Less commonly nurse practitioner,
psychiatrist, the patient, or a social worker were included in these
conferences.
We did not find any significant relationship between duration of
clinical experience or number of surgeries and the presence of a cut-off
in UPDRS part III improvement prior to proceeding with surgery, the
minimum duration of disease prior to DBS, whether the current FDA
approval for DBS in PD is considered earlier use, and what would qualify
as earlier use.

53.57%) were among the top three. No neurosurgeon required an
amantadine trial prior to surgery. Two out of 28 neurosurgeons (7.14%)
did not base their determination of DBS candidacy on trials of specific
medications.
When asked to rank their most important reasons to proceed with
DBS, presence of motor fluctuations not managed by medications was
selected by all interviewees (25/25) and received the most 1st place
votes with 12/25 (48%). Other important reasons were: dyskinesia not
managed by medications (24/25, 96%); significant quality of life
impairment (23/25, 92%); presence of medically-refractory tremor (20/
25, 80%); and 30% improvement in UPDRS with levodopa (17/25, 68%)
(Fig. 1, see also Table 1 Supplemental Digital Content 2).
Among reasons not to proceed with DBS the following were the most
common overall choices among respondents: unclear diagnosis (listed
by 22/25, 88%); severe cognitive impairment (20/25, 80%); unrealistic
expectations by the patient (19/25, 76%); lack of levodopa response
(16/25, 64%); medical contraindications to surgery (15/25, 60%);
psychiatric comorbidities (13/25, 52%); and lack of social and family
support (7/25, 28%) (Fig. 2, see also Table 2 Supplemental Digital
Content 3).
When asked to rank their top three choices regarding their personal
attitudes towards DBS, the response that received the most first and
second place votes was “DBS is more useful when used after the onset of
motor complications” (18/25, 72%). The response “DBS in PD allows for
a better management of symptoms than medications alone” was also a
frequently selected response. Neurosurgeons ranked very closely that
earlier DBS has either less or similar risks than when used later (Fig. 3,
see also Table 3 Supplemental Digital Content 4).
When asked about the minimum duration of disease before DBS
should be considered, ten of 25 surgeons (40%) indicated that three to
four years is the minimum duration, while four (16%) answered that
there is no minimum duration. No physician answered that seven or
more years of disease duration are required prior to DBS consideration.
Most participants (19/25, 76%) did not consider the FDA approval for
use in PD “of at least four years duration and with recent onset of motor
complications, or motor complications of longer-standing duration that
are not adequately controlled with medication” as earlier use.
When asked about how they counsel patients about having DBS
earlier versus later in the disease course, the most common answers
included: DBS replicates the best on state that can be obtained with
levodopa, which may decline with disease progression (16/23, 70%);
significant motor benefits (15/23, 65.2%); and the increasing risk of

4. Discussion
The aim of this study was to identify functional neurosurgeons’ at
titudes and perspectives around the use and timing of DBS for PD. The
possibility to continue shifting the use of DBS for PD earlier in the dis
ease progression has met with opinions ranging from groups advocating
for an even earlier use [17] and others warning against its risks [21].
Compared to prior observation from a survey published in 2016
identifying an average minimum duration of disease before DBS of five
to six years [19], a more recent survey indicated an average of less than
four years [20]. The fact that in our sample, most of the neurosurgeons
indicated four years or less or no minimum duration of disease before
DBS, may suggest a progressive trend toward earlier consideration.
Overall, the observed attitude in our sample appears to be in favor of
DBS at a stage which may be considered early compared to the most
recent FDA approval.
A small pilot study of 30 subjects suggested that early DBS, that is
prior to motor complication development, does not hasten PD progres
sion compared to medical treatment alone, maintains the benefits of
lower medication usage, as well as a similar rate of adverse events
compared to those nationally reported [17]. However, these results have

Fig. 1. Reasons to proceed with deep brain stimulation. Abbreviations: PD, Parkinson disease; UPDRS, Unified Parkinson’s Disease Rating Scale. Caption: Cumulative
ranking for each option, with each bar length determined by the sum of each answer count represented based on ranking.
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Fig. 2. Reasons not to proceed with deep brain stimulation. Abbreviations: DBS, deep brain stimulation. Caption: Cumulative ranking for each option, with each bar
length determined by the sum of each answer count represented based on ranking.

Fig. 3. Attitudes towards deep brain stimulation. Abbreviations: DBS, deep brain stimulation; PD, Parkinson disease. Caption. Cumulative ranking for each option,
with each bar length determined by the sum of each answer count represented based on ranking.

been strongly criticized because potentially unnecessary surgeries
caused adverse events in two out of 15 subjects, with one having per
manent neurological deficits [22]. Our results suggest that, while par
ticipants support the use of earlier DBS, they would only consider it after
the onset of motor complications, which typically occurs five years after
levodopa usage in approximately 50% of patients [12,23,24], and cite
motor complications among the main reasons to proceed with DBS.

Connected to the issue of whether or not DBS is more cost effective
than medication alone, published studies, which are based on predictive
models, have suggested earlier DBS as cost effective when considering
both an increase in medical care costs and the improvement in qualityadjusted life years with earlier DBS [8–10]. However, we only found that
a small number of participants held such a perspective. Patients in other
studies have reported challenges in returning to independence following
4

P. Testini et al.

Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 25 (2021) 101224

the onset of disability and loss of function [6,7], which may contribute
to earlier DBS-related improvement in quality-adjusted life years.
While our results demonstrated that age of patients is rarely a
detrimental factor for surgery, earlier DBS carries a theoretically higher
risk of hardware complications due to the longer duration of implanta
tion, and some of the surgical risks may be compounded by the potential
increased number of implantable pulse generator (IPG) changes [25].
With the advent of and increasing use of rechargeable IPGs, frequent
surgeries will be limited, potentially making earlier DBS more desirable
[26]. In fact, our study showed that most neurosurgeons think that
earlier DBS has either similar or fewer risks than later DBS, and only one
reported concern for higher complication risk, confirming previous
findings that for clinicians the risk profile is better in earlier DBS [21].
The most commonly cited reason not to proceed with DBS in our
survey was the concern for a misdiagnosis of atypical parkinsonism, and
although our survey did not specify whether this was a concern in earlier
DBS or in the overall patient population, this concern represents an
established argument against earlier application of DBS [21]. The
possible misdiagnosis of atypical parkinsonism as PD has been a clini
cian’s concern for decades [27]. A recent clinicopathological study
showed that the positive predictive value of a clinical diagnosis of
probable PD increases after five years of disease and with the presence of
motor complications [28]. While there is acknowledgement of this
concern, our sample still considered that three to four years is the
minimum duration of PD before DBS should be considered. There are
ongoing efforts in the scientific community to improve diagnostic ac
curacy with various imaging modalities [29–32] and other measures
including wearable sensor arrays [33]. However, until definitive diag
nostic conclusions can be drawn from imaging modalities, PD and
atypical parkinsonisms remain clinical diagnoses, potentially continuing
to limit early application of DBS.
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5. Limitations

Appendix A. Supplementary data

Limitations of the present study include the relatively low number of
responses. ASSFN membership is around 300, which would indicate a
response rate of just over 10%, and lower response rate for some sections
of the questionnaire. A 10–15% response rate on an online physiciandirected survey is common [34]. No participant demographic data
including age and gender were collected and therefore no observation
could be made regarding the correlation between age or gender and
attitudes toward DBS and its timing. In addition, the distributions of the
survey by ASSFN among its members likely provided a selection bias of
surgeons who are active in the ASSFN, limiting the generalizability of
the results.

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.inat.2021.101224.
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